Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Angiozyme

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Catalytic RNAanti-FLT-1 ribozyme

Narrower (1)

Ribozyme RPI.4610

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
An open‐label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer
Serum and plasma levels of vascular endothelial growth factor (VEGF) correlate with prognosis in patients with metastatic breast… 
Highly Cited
2005
Highly Cited
2005
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors
Purpose: This study intended to determine the maximum tolerated dose, safety, pharmacokinetic variables, clinical response, and… 
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
2004
2004
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
PurposeRPI.4610 (ANGIOZYME) is a chemically stabilized ribozyme targeting vascular endothelial growth factor receptor 1. The… 
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Review
2001
Review
2001
Angiozyme: A Novel angiogenesis inhibitor
Several inhibitors of angiogenesis are being developed for the treatment of cancer. One dominant strategy involves disruption of… 
Review
2000
Review
2000
Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.
The discovery of ribozymes by Cech and Altman has fundamentally changed the view of the function of RNA in chemistry, biology… 
  • figure 1
  • figure 2
  • figure 3
  • table 1
2000
2000
Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey.
The potential acute toxicity of a ribozyme (ANGIOZYME) targeting the flt-1 vascular endothelial growth factor (VEGF) receptor… 
2000
2000
Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens.
A significant amount of research has been devoted to the chemical stabilization of synthetic ribozymes, in part, so that… 
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE